SPC Financial Inc. lifted its position in Johnson & Johnson (NYSE:JNJ) by 3.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,050 shares of the company’s stock after buying an additional 150 shares during the quarter. SPC Financial Inc.’s holdings in Johnson & Johnson were worth $652,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Horan Securities Inc. lifted its holdings in Johnson & Johnson by 122.3% during the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock valued at $56,000 after purchasing an additional 241 shares during the last quarter. Stuart Chaussee & Associates Inc. lifted its holdings in Johnson & Johnson by 20.7% during the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after purchasing an additional 80 shares during the last quarter. FNY Investment Advisers LLC lifted its holdings in Johnson & Johnson by 594.4% during the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock valued at $64,000 after purchasing an additional 428 shares during the last quarter. CKW Financial Group lifted its holdings in Johnson & Johnson by 18.8% during the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock valued at $105,000 after purchasing an additional 128 shares during the last quarter. Finally, Mackey Komara & Dankovich LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at $148,000. 67.20% of the stock is owned by institutional investors and hedge funds.

JNJ opened at $139.05 on Friday. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13. The firm has a market cap of $373.06 billion, a PE ratio of 17.00, a PEG ratio of 2.40 and a beta of 0.67.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.07. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The company had revenue of $20.02 billion during the quarter, compared to the consensus estimate of $19.55 billion. During the same quarter last year, the firm earned $2.06 earnings per share. The company’s revenue was up .1% on a year-over-year basis. On average, sell-side analysts predict that Johnson & Johnson will post 8.6 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 11th. Stockholders of record on Tuesday, May 28th will be issued a dividend of $0.95 per share. The ex-dividend date is Friday, May 24th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.73%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. Johnson & Johnson’s dividend payout ratio (DPR) is currently 44.01%.

Several equities research analysts have issued reports on JNJ shares. Morgan Stanley raised their price target on Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a report on Wednesday, April 17th. Zacks Investment Research downgraded Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, January 16th. Citigroup raised their price target on Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a report on Monday, February 25th. BMO Capital Markets raised their price target on Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and set a $152.00 price target (down previously from $162.00) on shares of Johnson & Johnson in a report on Monday, January 14th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $146.90.

TRADEMARK VIOLATION WARNING: “SPC Financial Inc. Has $652,000 Position in Johnson & Johnson (JNJ)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2019/05/11/spc-financial-inc-has-652000-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: What kind of dividend yield to CEF’s pay?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.